I think your interpretation is correct. I'm hopeful that the renegotiated price came about as a result of some unannounced acquisition coming down the pipe. Now that Vinergy has freed up over 5 million shares, they've got some more puchasing power without having to dilute our shares further. This would be in MJ biopharma's interest if the next acquisition were to overcompensate for their reduced number of shares. Could just be that they couldnt find the money for the original agrreement though.
Just wanted to clarify that Vinergy isnt the one paying the money, they are paying in shares (4 million). Its my understanding that MJ biopharma is paying to be acquired (the $800,000) as a means of going public. While MJ would be at a loss at first, they would recoup those losses once Vinergy's value increases.
News 
Market Data 
Discover 
